Article
Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer.
Nature genetics - 1 Nov 2022
Petljak Mia, Green Abby M, Maciejowski John, Weitzman Matthew D
Abstract excerpt
Mutational signatures associated with apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC)3 cytosine deaminase activity have been found in over half of cancer types, including some therapy-resistant and metastatic tumors. Driver mutations can occur in APOBEC3-favored sequence contexts, suggesting that mutagenesis by APOBEC3 enzymes may drive cancer evolution. The APOBEC3-mediated signatures...
Topics
- Humans
- Mutagenesis
- Neoplasms
- APOBEC-1 Deaminase
- Mutation
- Cytidine Deaminase
- APOBEC Deaminases